Startseite>>Signaling Pathways>> PI3K/Akt/mTOR Signaling>> PI3K>>PI4KIIIbeta-IN-9

PI4KIIIbeta-IN-9

Katalog-Nr.GC32847

PI4KIIIbeta-IN-9 ist ein potenter PI4KIIIβ-Inhibitor mit einem IC50 von 7 nM. PI4KIIIbeta-IN-9 hemmt auch PI3Kδ und PI3Kγ mit IC50-Werten von 152 nM bzw. 1046 nM.

Products are for research use only. Not for human use. We do not sell to patients.

PI4KIIIbeta-IN-9 Chemische Struktur

Cas No.: 1429624-84-9

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
446,00 $
Auf Lager
1mg
83,00 $
Auf Lager
5mg
264,00 $
Auf Lager
10mg
446,00 $
Auf Lager
25mg
970,00 $
Auf Lager
50mg
1.586,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

PI4KIIIbeta-IN-9 is a potent PI4KIIIβ inhibitor with an IC50 of 7 nM. PI4KIIIbeta-IN-9 also inhibits PI3Kδ and PI3Kγ with IC50s of 152 nM and 1046 nM, respectively.

PI4KIIIbeta-IN-9 (Compound 9) shows weak inhibition of PI3KC2γ (IC50 ~1 µM), PI3Kα (~2 µM), and PI4KIIIα (~2.6 µM) and <50% inhibition at concentrations up to 20 µM for PI4K2α, PI4K2β, and PI3Kβ. PI4KIIIbeta-IN-9 (Compound 9) forms a crescent shape that conforms to the active site of PI4KIIIβ. This molecule makes extensive contacts with PI4KIIIβ[1].

[1]. Rutaganira FU, et al. Design and Structural Characterization of Potent and Selective Inhibitors of Phosphatidylinositol 4 Kinase IIIβ. J Med Chem. 2016 Mar 10;59(5):1830-9.

Bewertungen

Review for PI4KIIIbeta-IN-9

Average Rating: 5 ★★★★★ (Based on Reviews and 10 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PI4KIIIbeta-IN-9

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.